Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Recombinant human ADAMTS-13

EU orphan designation number: EU/3/08/588   
Active ingredient: Recombinant human ADAMTS-13
Indication: Treatment of thrombotic thrombocytopenic purpura
Sponsor: Baxalta Innovations GmbH
Industriestraße 67, 1221 Wien, Österreich

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/12/2008 Orphan designation EMEA/OD/056/08 (2008)8095 of 03/12/2008
15/04/2016 Transfer of orphan designation EMEA/OD/056/08/T/01 (2016)2261 of 13/04/2016